Literature DB >> 4057077

Dose-dependent pharmacokinetics of diflunisal in rats: dual effects of protein binding and metabolism.

J H Lin, K F Hooke, K C Yeh, D E Duggan.   

Abstract

The purpose of this study was to define the dual effects of saturable metabolism and saturable protein binding on the pharmacokinetics of diflunisal. Steady-state diflunisal concentration and its unbound fraction were examined in seven groups of rats to determine the relationships of infusion rate, concentration and total and unbound clearances. The total body plasma clearance decreased initially and then went up as the concentration of diflunisal increased, whereas the intrinsic clearance of unbound drug decreased with increasing concentration. The former is a consequence of saturable metabolism as well as saturable protein binding; the latter is a consequence of saturable metabolism. The fraction of unbound diflunisal increased with concentration. The biliary excretion data of ester and ether glucuronide suggested that both the ester and ether glucuronidation processes are capacity-limited, although the enzyme system for ether glucuronide has a lower Km and capacity than the system responsible for the ester glucuronidation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4057077

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Dose-dependent pharmacokinetics of MK-417, a potent carbonic anhydrase inhibitor, in experimental polycythemic and anemic rats.

Authors:  J H Lin; I W Chen; F A deLuna
Journal:  Pharm Res       Date:  1991-05       Impact factor: 4.200

2.  The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man.

Authors:  R K Verbeeck; G R Loewen; J I MacDonald; R J Herman
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

3.  Effect of albumin distribution. A simulation analysis of the effect of altered albumin distribution on the apparent volume of distribution and apparent elimination rate constant of drugs.

Authors:  M Shimoda; E Kokue; T Hayama; T B Vree
Journal:  Pharm Weekbl Sci       Date:  1989-06-23

4.  Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats.

Authors:  Xiaonan Li; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2017-02-28       Impact factor: 3.922

Review 5.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

6.  Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.

Authors:  L O Erikson; E Wåhlin-Boll; I Odar-Cederlöf; L Lindholm; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of nimesulide.

Authors:  A Bernareggi
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

8.  Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies.

Authors:  G R Loewen; R J Herman; S G Ross; R K Verbeeck
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

9.  Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics.

Authors:  M V Relling; R R Evans; S Groom; W R Crom; C B Pratt
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

Review 10.  Scaling basic toxicokinetic parameters from rat to man.

Authors:  K Bachmann; D Pardoe; D White
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.